Changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-controlled parallel-group study (Alzheimer’s Disease Acitretin Medication-ADAM)
Laufzeit: 01.01.2009 - 31.12.2012